Frank Diamond
Managing Editor
MANAGED CARE August 2009. ©MediMedia USA

A ‘health insurance czar’ might not make the final bill, if there is one, but the proposal evokes centuries-old tension

Managing Editor

We’re gambling. The “health choices commissioner,” a k a the health insurance czar, might not be an issue when you read this. The legislative process that promises to bring us health care reform might jettison the czar, or tweak the position so that it’s unrecognizable. In fact, as of this writing, the House version currently includes it, but the Senate version does not.

Yet the underlying tension — federal power vs. states’ rights — haunts our history and looms forever on our horizon. Also, things change quickly in Washington, D.C., these days, especially with health care. The czar might eventually become a prominent feature in both bills, and in the final law if there is one.

“I think there are going to be a lot of things thrown out and a lot of things thrown away over the course of the discussion,” says Kim Holland, who serves on the executive committee of the National Association of Insurance Commissioners. “What we’re experiencing here is the debate and part of the discussion about the role of the federal government in contrast to the role of the states. There’s some necessary tension. I think that with something as significant as health care, which affects all of our citizens, there’s going to be at least a bit of debate about the federal government’s role.”

States’ rights

That debate will continue no matter what the fate of the health insurance czar. States’ rights are at stake, says Robert Moffit, the health policy expert at the conservative Heritage Foundation. He looks askance at so much power being concentrated in the hands of one individual.

“The health choices commissioner will have a wide variety of really important and critical duties,” says Moffit. “He will run a national health insurance exchange. He will set standards for health plans. He will set rules for competition among private plans with the new public plan. He’ll determine what kind of plans can enter the national Health Insurance Exchange that will be the mechanism for competition between private health plans and the national health plan.”

Not surprisingly, consumer groups champion the idea. “We need a better health care cop on the beat,” William Vaughan, a senior policy analyst at Consumers Union, publisher of Consumer Reports, told the Associated Press early last month. “There needs to be a federal insurance commissioner to keep insurers on the straight and narrow.”

In a prepared statement, Ron Pollack, executive director of Families USA, also voiced support: “The House health care reform bill provides the right prescription for America’s ailing health care system. It offers an effective set of remedies to ensure that virtually all Americans have access to high-quality, affordable health coverage and care.”

The Health Insurance Exchange would theoretically allow small employers and individuals to shop for coverage packages among private and public insurers. It would be similar to the Commonwealth Health Insurance Connector Authority, which oversees the Massachusetts universal health insurance effort. “There are important differences,” says Moffit. “The connector is a state institution that was designed for a very specific purpose. In the connector, of course, you don’t have a public plan competing against private insurance.”

Karen Ignagni, president of America’s Health Insurance Plans, expressed similar reservations in testimony to the House Energy and Commerce Committee’s Subcommittee on Health on June 25.

“We have concerns that the proposed legislation delegates too much authority to the new health choices commissioner, and we would recommend that the legislation provide clear and consistent standards that could be implemented inside and outside the exchange,” Ignagni said. “Under the House bill, the health choices commissioner would be given broad authority over employer- and union-sponsored group health plans, group and individual health insurers, the public health insurance option, Federal Employees Health Benefits plans, and state and local government employee plans, as well as supervision of the Health Insurance Exchange and state-based exchanges.”

Hits home

AHIP spokesman Robert Zirkelbach says that the health insurance czar would have the sort of broad authority that will have a direct effect on how clinical administrators operate. “This commissioner would have authority over benefit packages, in their design and in the important role that the medical director plays. How exactly? How specific? We don’t know yet. That’s actually one of the issues. The legislation approves a very broad, sweeping authority and doesn’t get very specific as to exactly what role this entity would play as part of the broader regulatory structure.”

Holland, a Democrat who is the Oklahoma insurance commissioner, worries about encroachment on state authority, whether by a czar or some other federal mechanism. “How do the states ensure that they have the flexibility to address issues that are relevant to their own jurisdictions?” she asks. “Oklahoma, just as an example, is not like California, or Florida, or New York. We have our own unique issues, our own unique demographics and geographics that affect how we deliver health care.”

For instance, one of the duties of the health insurance czar would be to ensure the prompt payment of claims. “Well, states already have prompt-pay laws,” says Holland. “One of the responsibilities would be network management. I don’t really know what that means. I think it would be difficult for the federal government to know what kind of network needs I have here in Oklahoma. Or how our citizens would access a physician in a rural part of our state.”

Holland stresses that states have a myriad of laws that are similar, and yet are modified to meet a particular state’s needs. “That actually has worked quite well,” says Holland.


Holland appreciates the sense of urgency fueling health care reform. “At the same time, it is enormous,” says Holland. “We’ll deal with the consequences of our decision making for some time ahead. My hope is that we don’t rush to a conclusion without making sure that we’re making the right decisions and targeting the right problem. I would hope that we’d be very, very cautious.”

Don’t rush it, warns Kim Holland of the National Association of Insurance Commissioners, about efforts to reform health care. “We’ll deal with the consequences” for a very long time.

Employers on the hook

Opponents of creating a health choices commissioner — a health insurance czar — as part of health care reform say that the powers accorded this position in the House bill are too broad and ill-defined.

The bill establishes “an independent agency in the executive branch of the government, to be known as the ‘Health Choices Administration.’”

This HCA would be headed by a health choices commissioner who would be appointed by the president with the consent of the Senate. The commissioner “shall establish standards for the coordination of benefits and reimbursement of payments in cases involving individual and multiple plan coverage.”

There is no language in the bill that deals specifically with the commissioner/health plan relationship. The emphasis is mostly on employers, who will have to provide the commissioner with “such information as the commissioner may require....”

Employers will have to make a contribution “if such contribution is equal to an amount equal to 8 percent of the wages paid by the employer to such employee during the period of enrollment. Any such contribution shall be paid to the health choices commissioner for deposit into the Health Insurance Exchange Trust Fund....”

Perhaps more ominously, the commissioner will “have authority to set standards for determining whether employers are undertaking any actions to affect the risk pool within the Health Insurance Exchange by inducing individuals to decline coverage under a qualified health benefits plan ... offered by the employer and instead to enroll in an exchange-participating health benefits plan. An employer violating such standards shall be treated as not meeting the requirements of this section.”

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.